The Invicta Diagnostic IPO is a closed SME Bookbuilding offer (Fresh Capital) that opened on 1 December 2025. The Invicta Diagnostic IPO closed on 3 December 2025, with an issue price of ₹85 per share. The Invicta Diagnostic IPO has a face value of ₹10 and a lot size of 1,600 shares. The Invicta Diagnostic IPO is listed on 8 December 2025. The Invicta Diagnostic IPO allotment was scheduled for 4 December 2025.
On the financial front, the Invicta Diagnostic IPO reported revenue of ₹17 crore for 30 Sep 2025, compared with ₹30 crore for 31 Mar 2025. The Invicta Diagnostic IPO PAT was ₹4 crore against ₹5 crore. The Invicta Diagnostic IPO EBITDA stood at ₹7 crore with a 30.57% margin. The Invicta Diagnostic IPO net worth as of 30 Sep 2025 was ₹24 crore.
Always verify The Invicta Diagnostic IPO details and GMP data with the official offer document before investing in the Invicta Diagnostic IPO.
Financial Summary
Amount in ₹ Crore
Metric
30 Sep 2025
31 Mar 2025
31 Mar 2024
Total Assets
35
21
16
Revenue
17
30
16
PAT
4
5
4
EBITDA
7
9
7
Net Worth
24
14
9
Reserves
14
5
9
Total Borrowing
4
4
4
Invicta Diagnostic IPO Financials FAQs
Revenue of Invicta Diagnostic (Amount in ₹ Crore) — 30 Sep 2025: 17; 31 Mar 2025: 30; 31 Mar 2024: 16. Profit after tax (PAT) — 30 Sep 2025: 4; 31 Mar 2025: 5; 31 Mar 2024: 4.
EBITDA of Invicta Diagnostic (Amount in ₹ Crore) — 30 Sep 2025: 7; 31 Mar 2025: 9; 31 Mar 2024: 7. The EBITDA margin is 30.57%.
Total assets — 30 Sep 2025: 35; 31 Mar 2025: 21; 31 Mar 2024: 16. Net worth — 30 Sep 2025: 24; 31 Mar 2025: 14; 31 Mar 2024: 9. Reserves & surplus — 30 Sep 2025: 14; 31 Mar 2025: 5; 31 Mar 2024: 9. (Amount in ₹ Crore)
Total borrowing of Invicta Diagnostic (Amount in ₹ Crore) — 30 Sep 2025: 4; 31 Mar 2025: 4; 31 Mar 2024: 4. Debt-to-equity ratio: 0.26.
The financials shown for Invicta Diagnostic IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.